Abstract
For a single year, 1983, we compared the actual and estimated morbidity, mortality, and costs attributable to measles, mumps, and rubella with having or not having a childhood immunization program using the combined measles-mumps-rubella (MMR) vaccine. Without an immunization program, an estimated 3,325,000 cases of measles would occur as compared to 2,872 actual cases in 1983 with a program. Instead of an expected 1.5 million rubella cases annually, there were only 3,816 actual cases. Mumps cases were lowered from an expected 2.1 million to 32,850 actual cases. Comparable reductions in disease-associated complications, sequelae, and deaths are gained with an immunization program. Without a vaccination program, disease costs would have been almost $1.4 billion. Based on the actual incidence of disease in 1983, costs were estimated to be approximately +14.5 million. Expenditures for immunization, including vaccine administration costs and the costs associated with vaccine reactions, totaled $96 million. The resulting benefit-cost ratio for the MMR immunization program is approximately 14:1. The savings realized due to the use of combination rather than single antigen vaccine total nearly $60 million.
Full text
PDF





Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Albritton R. B. Cost-benefits of measles eradication: effects of a federal intervention. Policy Anal. 1978 Winter;4(1):1–21. [PubMed] [Google Scholar]
- Axnick N. W., Shavell S. M., Witte J. J. Benefits due to immunization against measles. Public Health Rep. 1969 Aug;84(8):673–680. [PMC free article] [PubMed] [Google Scholar]
- Buynak E. B., Weibel R. E., Whitman J. E., Jr, Stokes J., Jr, Hilleman M. R. Combined live measles, mumps, and rubella virus vaccines. JAMA. 1969 Mar 24;207(12):2259–2262. [PubMed] [Google Scholar]
- Koplan J. P., Axnick N. W. Benefits, risks and costs of viral vaccines. Prog Med Virol. 1982;28:180–191. [PubMed] [Google Scholar]
- Koplan J. P., Preblud S. R. A benefit-cost analysis of mumps vaccine. Am J Dis Child. 1982 Apr;136(4):362–364. doi: 10.1001/archpedi.1982.03970400080021. [DOI] [PubMed] [Google Scholar]
- Krugman R. D., Witte J. J., Parkman P. D., Herrmann K. L., Meyer H. M., Jr, Wende R. D., Meyer B. C., Dungca R. Combined administration of measles, mumps, rubella, and trivalent oral poliovirus vaccines. Public Health Rep. 1977 May-Jun;92(3):220–222. [PMC free article] [PubMed] [Google Scholar]
- Krugman S., Muriel G., Fontana V. J. Combined live measles, mumps, rubella vaccine. Immunological response. Am J Dis Child. 1971 May;121(5):380–381. doi: 10.1001/archpedi.1971.02100160050003. [DOI] [PubMed] [Google Scholar]
- LANGMUIR A. D. Medical importance of measles. Am J Dis Child. 1962 Mar;103:224–226. doi: 10.1001/archpedi.1962.02080020236005. [DOI] [PubMed] [Google Scholar]
- Landefeld J. S., Seskin E. P. The economic value of life: linking theory to practice. Am J Public Health. 1982 Jun;72(6):555–566. doi: 10.2105/ajph.72.6.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lerman S. J., Bollinger M., Brunken J. M. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics. 1981 Jul;68(1):18–22. [PubMed] [Google Scholar]
- Modlin J. F., Jabbour J. T., Witte J. J., Halsey N. A. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics. 1977 Apr;59(4):505–512. [PubMed] [Google Scholar]
- Nolan T. F., Jr, Goodman R. A., Patriarca P. A., Hinman A. R. Hospitalizations for measles, 1970-78. Am J Public Health. 1982 Sep;72(9):1037–1039. doi: 10.2105/ajph.72.9.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Preblud S. R., Serdula M. K., Frank J. A., Jr, Brandling-Bennett A. D., Hinman A. R. Rubella vaccination in the United States: a ten-year review. Epidemiol Rev. 1980;2:171–194. doi: 10.1093/oxfordjournals.epirev.a036221. [DOI] [PubMed] [Google Scholar]
- Schoenbaum S. C., Hyde JN Jr Bartoshesky L., Crampton K. Benefit-cost analysis of rubella vaccination policy. N Engl J Med. 1976 Feb 5;294(6):306–310. doi: 10.1056/NEJM197602052940604. [DOI] [PubMed] [Google Scholar]
- Schwarz A. J., Jackson J. E., Ehrenkranz N. J., Ventura A., Schiff G. M., Walters V. W. Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. Am J Dis Child. 1975 Dec;129(12):1408–1412. doi: 10.1001/archpedi.1975.02120490026008. [DOI] [PubMed] [Google Scholar]
- Weibel R. E., Buynak E. B., McLean A. A., Roehm R. R., Hilleman M. R. Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines. Proc Soc Exp Biol Med. 1980 Nov;165(2):260–263. doi: 10.3181/00379727-165-40967. [DOI] [PubMed] [Google Scholar]
- Witte J. J., Axnick N. W. The benefits from 10 years of measles immunization in the United States. Public Health Rep. 1975 May-Jun;90(3):205–207. [PMC free article] [PubMed] [Google Scholar]